SG11202103078WA - Compositions for reducing serum uric acid - Google Patents

Compositions for reducing serum uric acid

Info

Publication number
SG11202103078WA
SG11202103078WA SG11202103078WA SG11202103078WA SG11202103078WA SG 11202103078W A SG11202103078W A SG 11202103078WA SG 11202103078W A SG11202103078W A SG 11202103078WA SG 11202103078W A SG11202103078W A SG 11202103078WA SG 11202103078W A SG11202103078W A SG 11202103078WA
Authority
SG
Singapore
Prior art keywords
compositions
uric acid
serum uric
reducing serum
reducing
Prior art date
Application number
SG11202103078WA
Inventor
Johan Hoegstedt
James Mackay
Eva Johnsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202103078WA publication Critical patent/SG11202103078WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202103078WA 2018-10-01 2018-10-01 Compositions for reducing serum uric acid SG11202103078WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/057612 WO2020070539A1 (en) 2018-10-01 2018-10-01 Compositions for reducing serum uric acid

Publications (1)

Publication Number Publication Date
SG11202103078WA true SG11202103078WA (en) 2021-04-29

Family

ID=63965710

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103078WA SG11202103078WA (en) 2018-10-01 2018-10-01 Compositions for reducing serum uric acid

Country Status (13)

Country Link
US (1) US20210338648A1 (en)
EP (1) EP3860601A1 (en)
JP (1) JP2022511380A (en)
KR (1) KR20210069685A (en)
CN (1) CN112789041A (en)
AU (1) AU2018444285A1 (en)
BR (1) BR112021006002A2 (en)
CA (1) CA3113376A1 (en)
EA (1) EA202190841A1 (en)
IL (1) IL281740A (en)
MX (1) MX2021003845A (en)
SG (1) SG11202103078WA (en)
WO (1) WO2020070539A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252630A1 (en) * 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
BR112023000406A2 (en) 2020-07-10 2023-01-31 Astrazeneca Ab COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use
KR20230119303A (en) * 2022-02-07 2023-08-16 (주)인드림헬스케어 A pharmaceutical composition comprising allopurinol, febuxostat or a pharmaceutically acceptable salt thereof for the prevention or treatment of chronic kidney disease in a subject having high blood uric acid concentration
WO2023149701A1 (en) * 2022-02-07 2023-08-10 (주)인드림헬스케어 Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high blood uric acid level

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2725047A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
CN106176736A (en) * 2010-10-15 2016-12-07 阿迪亚生命科学公司 For the method treating hyperuricemia and relevant disease
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1

Also Published As

Publication number Publication date
WO2020070539A1 (en) 2020-04-09
US20210338648A1 (en) 2021-11-04
EP3860601A1 (en) 2021-08-11
BR112021006002A2 (en) 2021-06-29
AU2018444285A1 (en) 2021-05-20
IL281740A (en) 2021-05-31
MX2021003845A (en) 2021-05-27
CA3113376A1 (en) 2020-04-09
JP2022511380A (en) 2022-01-31
KR20210069685A (en) 2021-06-11
EA202190841A1 (en) 2021-07-15
CN112789041A (en) 2021-05-11

Similar Documents

Publication Publication Date Title
IL281740A (en) Compositions for reducing serum uric acid
IL277006A (en) Cd73 inhibitors
EP3843714A4 (en) Cd73 inhibitors
IL288613A (en) Multispecific proteins
IL304348A (en) Cd73 inhibitors
EP3587576A4 (en) Antisense oligonucleic acid
EP3277757A4 (en) Compositions for inhibiting corrosion
EP3186353A4 (en) Solid rinse aid composition comprising polyacrylic acid
EP4051688A4 (en) Cd73 inhibitors
PT3481819T (en) Compounds and their use for reducing uric acid levels
EP3749777A4 (en) Compositions and techniques for nucleic acid primer extension
SG11202110534QA (en) Cd73 inhibitors
EP3309259A4 (en) Method for producing -hydromuconic acid
EP4069731A4 (en) Nucleic acid linked immune-sandwich assay (nulisa)
EP4032551A4 (en) Nucleic acid complex
EP3266461A4 (en) Composition for improving or preventing nonalcoholic fatty liver
EP3360957A4 (en) Composition for rapidly separating adipose tissue-derived stromal cells
EP3632904A4 (en) Urat1 inhibitor for promoting uric acid excretion
SG11202001327RA (en) Composition for reducing serum uric acid level
ZA202101836B (en) Compositions containing linoleic acid
EP4076343C0 (en) Retinol-based serum
EP3894581A4 (en) Nucleic acid biomarkers for placental dysfunction
EP3903792A4 (en) Prebiotic composition for butyric acid bacteria
EP3766972A4 (en) Nucleic acid complex
EP3716966A4 (en) Alpha keto acid compositions for treating hypo-albuminemia